FOLR1 and hepatocellular carcinoma: Therefore, we next pursued the potential of FOLR1 as a blood-based biomarker for HCC patients by evaluating the serum of 247 patients diagnosed with HCC and 238 patients diagnosed with chronic hepatitis C (CHC) without HCC, along with 50 patients diagnosed with colon polyps without liver disease who served as normal controls.